[Screening for hemolytic streptococcus group B in pregnancy and prevention of infection in neonates].
OBJECTIVE
The aim of this study was to evaluate the influence of Group B streptococcus (GBS) screening and intrapartum antibiotic prophylaxis to the incidence of GBS disease in newborns.


METHODS
Prospective non-randomised study.


METHODS
IInd Clinic of Obstetric and Gynaecology LFUK and FNsP Ruzinov, Bratislava, Slovakia.


METHODS
We enrolled 3023 newborns (754 in the study group, 2269 in the control group), which were born between 1.9.2000 and 31.3.2003. In both groups we compared following variables: total number of infectious diseases in newborns, number and forms of GBS neonatal disease, number of perinatal death due to GBS disease.


RESULTS
There was no GBS disease in the study group of 754 newborns. Mothers of these newborns had one screening culture in 35-36th week of gestation. One swab was taken from vagina and anus. GBS carriers (161-21.4%) were administered i.v. intrapartum antibiotic prophylaxis with Penicillin G i.v., or, when allergy to penicillin was in history, with Clindamycin i.v. In the control group of 2269 newborns, whose mothers had no prevention, the incidence of GBS neonatal disease reached 7.5/1000 newborns (17 cases). The incidence of invasive GBS neonatal disease was 2.6/1000 newborns.


CONCLUSIONS
The authors have noticed a significant decrease in incidence of GBS neonatal disease after implication of GBS screening and intrapartum antibiotic prophylaxis.
Janek
L
L
II. gynekologicko-pôrodnícka klinika LFUK a FNsP, Ruzinov, Bratislava, Slovenská republika.
Holomán
K
K
Suska
P
P
Gavorník
E
E
Horáková
E
E
Krizko
M
M
D001003:Anal Canal / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002353:Carrier State / Q000175:diagnosis*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis* / Q000188:drug therapy; D013290:Streptococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000302:isolation & purification*; D014621:Vagina / Q000382:microbiology
D000900:Anti-Bacterial Agents